News & Information

UPDATE: EcoActive™ Bacteriophage Therapy Enters Clinical Trial at the Mount Sinai Hospital

Intralytix, Inc.'s EcoActive™ bacteriophage therapy targeting adhesive invasive E. coli (AIEC) in Crohn's disease patients has entered a Phase 1/2a clinical trial at the Icahn School of Medicine at the Mount Sinai Hospital in New York, NY. The trial, registered under NCT03808103, is currently recruiting volunteers with inactive Crohn's disease.

For questions on the phage study, please contact the study coordinator at

See one of the trial's clinical investigators and IBD expert, Dr. Robert Hirten, discuss this exciting new bacteriophage therapy trial at:

Feb 08, 2019

Back to news archive


Food Safety

Environmental Sanitation

Veterinary Applications

Human Therapeutics